CMS Approval Will Mark ‘Starting Gate’ For Leqembi Launch For Biogen

Biogen will likely add sales reps to support Eisai’s US commercial launch of the Alzheimer’s drug early next year when treatment capacity increases.

starting gate
Biogen plans to start investing more in Leqembi after CMS grants reimbursement • Source: Shutterstock

More from Neurological

More from Therapy Areas